SurVaxM is a peptide-based vaccine that targets survivin. Survivin is a peptide which is presented the cancer cells and is not present in the normal cells. We have found survivin expression in almost ...

CNW/ -- (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating ...

The vaccine, called SurVaxM, targets a protein found in tumors called survivin, named for the role it’s thought to play in the survival of cancer cells. Get rid of survivin, the thinking goes ...

SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma cells. We conducted a phase IIa ...

Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could ...

This patent application protects the use of our patented survivin mRNA both as a stand-alone vaccine and as an immunotherapy. Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK ...